Charlotte's Web (CWBHF) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
8 Jul, 2026Executive summary
Q2 2024 revenue was $12.3M, down 23.2% year-over-year, but marked the first sequential Q2 increase since 2021, driven by new products and expanded Walmart distribution.
B2B retail segment improved 8.8% over Q1, while D2C completed e-commerce migration, temporarily impacting June sales but showing strong July performance.
Significant cost reductions and operational efficiencies, including workforce reductions, lowered SG&A by 25% year-over-year.
Net loss for Q2 was $11M or $0.07 per share, compared to net income of $2.8M in Q2 2023, which included a $10.7M gain from DeFloria LLC formation.
Launched new CBN 'Stay Asleep' gummies and expanded retail presence, including Walmart partnership.
Financial highlights
Q2 net revenue was $12.3M, down from $16M year-over-year, but up from $12.1M in Q1; six-month revenue was $24.4M, down 26.1% year-over-year.
Gross margin for Q2 2024 was 21% due to a $3.8M non-cash inventory provision; adjusted gross margin was 52.2% (vs. 56.5% in Q2 2023).
Operating loss for Q2 2024 was $12.1M; adjusted EBITDA loss was $5.2M.
Cash and cash equivalents at June 30, 2024, were $32.5M, with $38.5M in working capital.
Cash flow for Q2 was -$6M; net cash used in operations for the first half of 2024 was $11.9M.
Outlook and guidance
Expense reductions are expected to lower SG&A by over $20M for the year, with a break-even cost structure at $65M annual net revenue.
Gross margin is expected to remain in the low- to mid-fifties for the remainder of the year, with improvement as in-house gummy production ramps up.
Management anticipates meeting liquidity requirements for at least the next twelve months through cash on hand and operations.
Optimism for revenue growth in 2025, supported by new e-commerce capabilities, product launches, and expanded retail partnerships.
Ongoing regulatory changes in several states may impact product formulations, packaging, and revenue.
Latest events from Charlotte's Web
- Transformed balance sheet, renewed growth, and Medicare pilot position drive future upside.CWBHF
Q4 20258 Jul 2026 - Market-leading CBD innovator, recapitalized for growth and positioned for regulatory-driven expansion.CWBHF
Investor presentation10 Jun 2026 - All resolutions passed, with BAT gaining 40% ownership and a Medicare pilot seen as a major growth driver.CWBHF
AGM 202628 May 2026 - Q1 2026 revenue dropped 9% and net loss widened, with a major BAT debt deal pending approval.CWBHF
Q1 202613 May 2026 - Returned to growth as the #1 CBD brand, leveraging innovation, partnerships, and regulatory momentum.CWBHF
Investor presentation26 Apr 2026 - Shareholders to vote on BAT transaction, director elections, and key governance matters.CWBHF
Proxy filing16 Apr 2026 - Key votes include director elections and a debenture amendment that may shift company control.CWBHF
Proxy filing16 Apr 2026 - Shareholders to vote on BAT's conversion to a control person, reshaping ownership and governance.CWBHF
Proxy filing6 Apr 2026 - BAT's investment and debenture conversion will give it 40.8% ownership and expanded governance rights.CWBHF
Proxy filing1 Apr 2026